In This Section
Appropriate Use Criteria for FDG PET/CT Restaging and Response Assessment of Malignant Disease
The new AUC for FDG PET/CT addresses several clinical scenarios for restaging and response assessment of malignant disease. To improve utilization and guide providers across specialties to use FDG-PET, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM), and the American Society of Clinical Oncology (ASCO) have collaboratively developed criteria for the appropriate use of this imaging technology to aid in the restaging and response assessment of people with malignant diseases.
SNMMI assembled a PET/CT Workgroup consisting of experts in the field of nuclear medicine including physicians, radiologists (diagnostic and pediatric), oncologists, and biomedical engineers to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the PET/CT Workgroup put together, which they used to make their recommendations for clinical use. This AUC addresses the CMS priority clinical area of cancer of the lung (primary or metastatic, suspected or diagnosed).
Click here to find a series of one-page factsheets on FDG PET/CT.
To view the development process, please click the following link: SNMMI AUC Development Process.